logo-loader
HealthPharma & Biotech
Abcam

Abcam on track to meet its full-year target after posting top line growth of 11% in the first half

The company specialises in supplying antibodies and immunoassays to the life sciences research sector

researcher filling vials
The company continued to gain market share

Abcam PLC (LON:ABC), which supplies antibodies for research, said it is on track to meet its full-year 2019 financial targets after posting double-digit first-half growth.

In an update, it said revenues grew by 11% on a reported basis or 10% at constant at currencies.

READ: Abcam shares tumble as outlook misses expectations despite double-digit earnings growth in full year

Abcam said it continued to gain market share in the global research market, particularly in the areas of recombinant antibodies and immunoassays. Expansion in China has also helped underpin its success.

"Global demand is strong for precision life science tools and Abcam has once again gained market share in these growing markets.  Our business is on track to achieve double-digit growth for the year,” said chief executive Alan Hirzel.

"During the half, we have continued to focus on improving our service for customers.

“We have further developed our product portfolio and we have continued to enhance our organisational capabilities to support our ambition of becoming the most influential company for life scientists, supporting research, diagnostic and therapeutic discovery."

Quick facts: Abcam

Price: £11.50

Market: AIM
Market Cap: £2.37 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Clear Leisure CEO confident of a positive outcome to its litigation issues

Francesco Gardin, chief executive and executive chairman of Clear Leisure PLC (LON:CLP), updates Proactive London on the firm's investments and ongoing litigation cases. This week the company's subsidiary, Clear Leisure 2017, agreed with Sipiem to buy the €10.8m legal action against the...

2 days, 5 hours ago

2 min read